Hengrui Medicine's Famitinib Malate Capsules and other drugs have been approved for clinical trials

On December 6, Hengrui Medicine issued an announcement stating that the company and its subsidiaries Suzhou Shengdia Biopharmaceutical Co.

In May 2019, Karelizumab for injection (trade name: Erica) was approved for the treatment of relapsed or refractory classic Hodgkin’s lymphoma after at least second-line chemotherapy; March 2020 , Approved for the treatment of patients with advanced hepatocellular carcinoma who have previously received sorafenib treatment and/or oxaliplatin-containing system chemotherapy; in June 2020, approved for the combination of pemetrexed and carboplatin for epidermis Growth factor receptor (EGFR) gene mutation-negative and anaplastic lymphoma kinase (ALK)-negative, unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) first-line treatment, and for previous acceptance Treatment of locally advanced or metastatic esophageal squamous cell carcinoma patients with disease progression or intolerance after first-line chemotherapy; May 2021, approved for advanced nasopharyngeal disease or intolerable advanced nasopharynx after previous second-line chemotherapy or above Treatment of cancer patients; in June 2021, the combination of cisplatin and gemcitabine was approved for the first-line treatment of patients with locally recurring or metastatic nasopharyngeal carcinoma

Famitinib Malate Capsules is a small molecule multi-target tyrosine kinase inhibitor

SHR-1802 for injection is a humanized monoclonal antibody that can activate and promote anti-tumor T cell responses, exert anti-tumor effects, and be used for advanced malignant tumors that have failed standard treatments